SLC6A4 rs4251417: Understanding This Common Genetic Variant
The rs4251417 variant is a common genetic change located within the SLC6A4 gene, which encodes the serotonin transporter protein. Research has explored its potential associations with stress resilience and psychiatric health, though current evidence remains limited and inconclusive.
What each genotype means
Typical physiological stress reactivity
You carry two copies of the common G allele for this variant in the SLC6A4 serotonin transporter gene. In candidate gene studies, individuals with this baseline genotype typically demonstrate standard cortisol output and stress responses during acute extreme stress compared to minor allele carriers. However, evidence connecting this specific single nucleotide polymorphism to stress resilience is limited and has not been broadly validated across diverse populations.
Carried by approximately 70% to 80% of individuals globally, representing the most common genotype across most ancestral groups.
Moderate stress resilience association
You carry one copy of the minor A allele and one copy of the common G allele. Preliminary research has linked the presence of the A allele with altered hypothalamic-pituitary-adrenal (HPA) axis cortisol reactivity and higher psychological resilience under acute extreme stressors, such as military survival training. Because overall scientific evidence remains limited and preliminary, this genotype should not be viewed as a definitive predictor of personal coping ability.
Carried by approximately 18% to 25% of individuals across global populations.
Potential enhanced stress resilience
You carry two copies of the minor A allele in the SLC6A4 gene. Early observational research in cohorts exposed to high physical and mental stress indicates that the A allele may correlate with modulated acute cortisol release and greater psychological resilience. However, evidence remains limited and exploratory, and many complex genetic and environmental factors shape overall stress tolerance.
Carried by approximately 1% to 3% of individuals globally, reflecting the relative infrequency of the minor homozygous state.
What is rs4251417?
The rs4251417 variant is a single nucleotide polymorphism (SNP) located within an intron of the SLC6A4 gene. In genetics, an intron is a non-coding region of a gene that is transcribed into RNA but removed before the final protein is produced. While intronic variants do not change the amino acid sequence of a protein directly, they can sometimes influence how a gene is regulated or expressed. This specific SNP is considered a common variant, meaning it appears frequently across diverse human populations. Because it sits within the serotonin transporter gene, researchers have long been interested in whether this variant might influence how the brain processes serotonin, a neurotransmitter critical for mood regulation and stress response.
The Role of the SLC6A4 Gene
The SLC6A4 gene provides instructions for making the serotonin transporter (SERT) protein. This protein is responsible for moving serotonin from the space between neurons (the synaptic cleft) back into the nerve cells, a process known as reuptake. By controlling the amount of serotonin available in the synapse, the serotonin transporter plays a vital role in modulating mood, anxiety, and sleep. Because of its central function, the SLC6A4 gene is a primary target for many antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs). Scientists study variants in this gene to understand if genetic differences might explain why some individuals respond differently to stress or psychiatric treatments than others.
Research and Evidence Strength
Scientific research into rs4251417 has yielded mixed results, and the evidence supporting its clinical significance is currently limited. Some preliminary studies have suggested a potential link between this variant and self-assessed resilience in high-stress environments, such as military training. Other research has investigated whether this SNP, alongside other SLC6A4 variants, influences DNA methylation patterns or susceptibility to depression. However, these findings are often preliminary or show only nominal statistical significance. Importantly, major reviews and clinical guidelines emphasize that SLC6A4 variants, including rs4251417, do not currently provide enough reliable information to guide clinical decisions regarding antidepressant therapy. The complex nature of psychiatric health means that many factors, including environment and other genes, contribute to these outcomes.
What You Can and Cannot Do With This Information
It is important to view genetic information about rs4251417 as a subject of ongoing scientific inquiry rather than a diagnostic tool. You cannot use this information to predict your personal risk for depression, your resilience to stress, or how you will respond to specific medications. Genetic associations observed in research studies are statistical trends across large groups and do not necessarily apply to any single individual. If you are concerned about your mental health or are considering changes to your medication, you must discuss these topics with a qualified clinician or pharmacist. They can provide personalized guidance based on your medical history, symptoms, and established clinical standards, which currently do not include routine testing for this specific variant.
How common is this variant?
The rs4251417 variant is considered a common SNP, with the C and T alleles appearing at varying frequencies across different global ancestral populations.
Frequently asked questions
Can I use rs4251417 to predict my antidepressant response?
No. Current clinical guidelines and systematic reviews state that there is insufficient evidence to use SLC6A4 variants, including rs4251417, to guide antidepressant treatment. Always consult your doctor regarding medication choices.
Is rs4251417 a 'depression gene'?
No. Depression is a complex condition influenced by many genetic, environmental, and lifestyle factors. A single SNP like rs4251417 does not determine whether someone will develop depression.
What does it mean if my report says this variant has 'limited' evidence?
Limited evidence means that while some studies have explored a potential link, the findings are not consistent, are preliminary, or have not been replicated in large-scale clinical trials. It suggests that the association is not strong enough to be used for medical decision-making.
Should I change my medication based on my SLC6A4 genotype?
Never change your medication or dosage based on genetic test results without speaking to your healthcare provider. Only a clinician can evaluate your treatment plan safely.
Sources & further reading
Educational information only, last refreshed 10/24/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4251417?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC6A4
3' UTR variant in the serotonin transporter gene influencing mRNA stability and emotional stress susceptibility in interaction with environmental trauma.
This variant (often studied alongside 5-HTTLPR) is located in the promoter region of the serotonin transporter gene; however, clinical evidence for its utility in predicting antidepressant response remains inconsistent and non-actionable.
A functional A/G variant within the 5-HTTLPR locus of the serotonin transporter gene. While historically hypothesized to modulate stress reactivity, large-scale replication studies and meta-analyses have largely failed to confirm consistent associations with psychiatric phenotypes or treatment response.